Seek urgent medical help if severe symptoms develop
Most patients notice subtle appetite reduction by day two or three, with more pronounced fullness and reduced cravings by days four through seven
Weight loss injections, particularly glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy, Ozempic) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Zepbound, Mounjaro), have transformed obesity management in recent years
What semaglutide dose equals my tirzepatide dose
The difference: Mounjaro is only approved to treat type 2 diabetes, while Zepbound is only approved to treat people with obesity or with overweight and a secondary condition like hypertension, type 2 diabetes, or sleep apnea
adults with type 2 diabetes are now eligible for GLP-1 or SGLT-2 therapies, demonstrating guideline-driven expansion of demand